Hydroxyprogesterone caproate
Delalutin (hydroxyprogesterone caproate) is a small molecule pharmaceutical. Hydroxyprogesterone caproate was first approved as Hydroxyprogesterone caproate on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hydroxyprogesterone caproate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HYDROXYPROGESTERONE CAPROATE | Allergan | N-017439 DISCN | 1982-01-01 | 2 products |
| DELALUTIN | Bristol Myers Squibb | N-010347 DISCN | 1982-01-01 | 2 products, RLD |
| DELALUTIN | Bristol Myers Squibb | N-016911 DISCN | 1982-01-01 | 2 products, RLD |
| HYDROXYPROGESTERONE CAPROATE | Epic Pharma | N-018004 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| hydroxyprogesterone caproate | ANDA | 2022-06-22 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
Clinical
Clinical Trials
181 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Contraception | D003267 | — | — | 9 | 3 | 1 | 7 | 8 | 26 |
| Premature birth | D047928 | EFO_0003917 | O60 | 1 | 5 | 11 | 2 | 9 | 25 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | 9 | 3 | 1 | 1 | 12 |
| Infertility | D007246 | EFO_0000545 | — | — | — | 2 | 4 | 4 | 10 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 2 | 1 | 1 | 3 | 9 |
| Syndrome | D013577 | — | — | — | 1 | 1 | 1 | 4 | 7 |
| Endometrial hyperplasia | D004714 | — | N85.0 | — | 3 | 3 | 2 | — | 7 |
| Hiv | D006678 | — | O98.7 | — | 1 | — | 3 | 3 | 7 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | 2 | 4 | 6 |
| Hyperplasia | D006965 | EFO_0000536 | — | 1 | 2 | — | 1 | — | 4 |
Show 17 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | 4 | — | 2 | 6 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | 6 | — | — | 6 |
| Endometrioid carcinoma | D018269 | — | — | 1 | 3 | 1 | — | 1 | 5 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | 4 | — | 1 | 5 |
| Coronary disease | D003327 | — | — | — | 1 | 5 | — | — | 5 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | 5 | — | — | 5 |
| Postmenopause | D017698 | — | — | 1 | — | 4 | — | — | 5 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | 2 | 2 | — | — | 5 |
| Menopause | D008593 | EFO_0003922 | N95 | — | 2 | 2 | — | — | 4 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 3 | — | — | 4 |
Show 32 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Congenital adrenal hyperplasia | D000312 | — | E25.0 | 1 | 2 | — | — | — | 3 |
| Depression | D003863 | — | F33.9 | — | 2 | — | — | 1 | 3 |
| Placenta previa | D010923 | EFO_0007442 | O44 | — | 1 | — | — | 2 | 3 |
| Neoplasms | D009369 | — | C80 | — | 2 | — | — | — | 2 |
| Bulimia | D002032 | — | F50.2 | — | 1 | — | — | — | 1 |
| Feeding and eating disorders | D001068 | — | F50 | — | 1 | — | — | — | 1 |
| Bulimia nervosa | D052018 | EFO_0005204 | F50.2 | — | 1 | — | — | — | 1 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | 1 | — | — | — | 1 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | 1 | — | — | — | 1 |
| Premature rupture fetal membranes | D005322 | — | O42 | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postcoital contraception | D044363 | — | — | 1 | — | — | — | 1 | 2 |
| Disorders of sex development | D012734 | — | Q56.3 | 1 | — | — | — | 1 | 2 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | — | 1 |
| Inborn genetic diseases | D030342 | EFO_0000508 | — | 1 | — | — | — | — | 1 |
| Hereditary congenital and neonatal diseases and abnormalities | D009358 | — | — | 1 | — | — | — | — | 1 |
| Urogenital abnormalities | D014564 | — | — | 1 | — | — | — | — | 1 |
| Adrenal gland diseases | D000307 | — | E27.9 | 1 | — | — | — | — | 1 |
| Inborn errors steroid metabolism | D043202 | — | — | 1 | — | — | — | — | 1 |
| Adrenocortical hyperfunction | D000308 | EFO_1000797 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Uterine hemorrhage | D014592 | — | — | — | — | — | — | 3 | 3 |
| Periodontal diseases | D010510 | — | K05.6 | — | — | — | — | 1 | 1 |
| Dental caries | D003731 | EFO_0003819 | K02 | — | — | — | — | 1 | 1 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | — | — | 1 | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | — | 1 | 1 |
| Executive function | D056344 | — | — | — | — | — | — | 1 | 1 |
| Microbiota | D064307 | — | — | — | — | — | — | 1 | 1 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | — | — | — | 1 | 1 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | — | — | — | 1 | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
Show 27 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Hydroxyprogesterone caproate |
| INN | hydroxyprogesterone caproate |
| Description | Hydroxyprogesterone caproate is a corticosteroid hormone. |
| Classification | Small molecule |
| Drug class | progestins; steroids (androgens, anabolics); antiandrogens |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C |
Identifiers
| PDB | — |
| CAS-ID | 630-56-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200848 |
| ChEBI ID | 5812 |
| PubChem CID | 169870 |
| DrugBank | DB06789 |
| UNII ID | 276F2O42F5 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,046 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
23,087 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use